___

• 1. Adamkiewitcz TV, Lorenzana A, Doyle J et al: Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward, Pediatr Infect Dis 1999;18:556-8.
• 2. AddockKA,AkinsRL,Farrington EA: Evaluation ofempiric vancomycin therapy in children with fever and neutropenia, Pharmacotherapy 1999; 19:1315-20.
• 3. Agaoglu L, Devecioglu O, Anak S et al: Cost-effectiveness of cefepime plus netilmicin or ceftazidime plus amikacin ormeropenemmonotherapy in febrile neutropenic children with malignancy in Turkey, J Chemother 2001;13:281-7.
• 4. Alexander SW,Walsh TJ, FreifeldAG, Pizzo PA: Infectious complications in pediatric cancer patients, “Pizzo PA, Poplack DG (eds): Principles and Practice of PediatricOncology, 4th ed.” kitabında s.1239-83, Lippincott Williams and Wilkins, Philadelphia (2002).
• 5. Allen U, Smith CR, Prober CG: The value of skin biopsies in febrile, neutropenic, immunocompromised children,Am J Dis Child 1986;140: 459-61.
• 6. Baorto EP,Aquino VM, Mullen CAet al: Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia, Cancer 2001;92:909-13.
• 7. Caillot D, Cassasnovas O, Bernard A et al: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thorasic computed tomographic scan and surgery, J ClinOncol 1997;15: 139-47.
• 8. Cometta A, Calandra F, Gaya H et al: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer, Antimicrob Agents Chemother 1996;40:1108-15.
• 9. Crokaert F: Febrile neutropenia in children, Int J AntimicrobialAgents 2000;16:173-6.
• 10. Düzova A, Kutluk T, Kanra G et al: Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors, Turk J Pediatr 2001;13:105-9.
• 11. Engel A, Steinbach G, Kern P et al: Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: Comparison with interleukin-8, Scand J Infect Dis 2001;32:832-5.
• 12. ForbesBA, SahmDF,WeissfeldAS:Bailey-Scott’sDiagnosticMicrobiology, 11th ed., Mosby, St. Louis (2002).
• 13. FreifeldAG,Walsh TJ, Pizzo PA: Infectious complications in the pediatric cancer patients, “Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology, 3rd ed.” kitabında s.1069-95, JP Lippincott, Philadelphia (1997).
• 14. Gözdaşoğlu S, Ertem M, Büyükkeçeci Z et al: Fungal colonization and infection in children with acute leukemia and lymphoma during induction therapy, Med Ped Oncol 1999;32:344-8.
• 15. Guerrant RL, Van Gilder T, Steiner TS et al: Practice guidelines for the management of infectious diarrhea, Clin Infect Dis 2001;32:331-50.
• 16. Hann L, Viscoli C, Paesmans M, Goya H, Glauser M and IATCG of EORTC: A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies, Brit J Haematol 1997;99:580-8.
• 17. Hughes WT, Armstrong D, Bodey GP et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patientswith cancer, Infectious Diseases Society of America, Clin Infect Dis 2002;34:730-50.
• 18. Jones GR, Konslet GK, Pusek SN: Infection risk factors in febrile, neutropenic children and adolescents, Pediatr Hematol Oncol 1996; 13:217-29.
• 19. Kebudi R, Devecioğlu Ö, Gürler N: Pediatrik febril nötropeni kılavuzu: Tanımlar ve tanı yöntemleri, Flora 2004;9:73-105.
• 20. Kebudi R, Görgün Ö,Ayan İ, Gürler N,Akıcı F, Töreci K:Arandomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors,Med Ped Oncol 2001;36:434-41.
• 21. Kern WF: Modifications of therapy, Int JAntimicrob Agents 2000;16: 139-41.
• 22. Klaasen RJ, Allen U, Doyle JJ: Randomized placebocontrolled trial of oral antibiotics in pediatric oncology patients at low-risk for fever and neutropenia, J Pediatr Hematol Oncol 2000;22:405-11.
• 23. Klaasen RJ, Goodman R, Pham B, Doyle JJ: “Lowrisk” prediction rule for pediatric oncology patients, J Clin Oncol 2000;18:1012-9.
• 24. Kocak U, Rolston KVI, Mullen CA: Fever and neutropenia in children with solid tumors is similar in severity and outcome to that in children with leukemia, Support Case Cancer 2002;10:58-64.
• 25. Lau RC, Doyle JJ, Freedman MH, King SM, Richardson ST: Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics, Pediatr Hematol Oncol 1994;11;417-21.
• 26. Lehrbecher T, Venson D, deHaas M et al: Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia, Clin Infect Dis 1999;29:414-9.
• 27. Mahon CR, Manuselis G: Diagnostic Microbiology, WB Saunders Co., Philadelphia (2000).
• 28. Mermel LA, Farr BM, Sheretz RJ et al: Guidelines for the management of intravascular catheter-related infection, Clin Infect Dis 2001;32:1249-72.
• 29. MillerMJ:AGuide to SpecimenManagement in ClinicalMicrobiology, ASM Press, Washington DC (1996).
• 30. Mucozzi A, Venditti M, Amadoris S et al: Teicoplanin in the treatment of gram positive bacteremia in neutropenic patients, Br J Hematol 1990; 76:19-23.
• 31. Mustafa MM, Carlston L, Tkaczewski I, McCracken GH, Buchanan GR: Comparative study of cefepime versus ceftazidime in the empiric treatment of cancer patients with fever and neutropenia, Pediatr Infect Dis J 2001;20:362-9.
• 32. Özturk R: Kateter infeksiyonlarında klinik tanı ve tedavi, ANKEM Derg 2000;14:460-7.
• 33. PaesmansM:Risk factors assessment in febrile neutropenia, Int JAntimicrob Agents 2000;16:107-11.
• 34. Paganini HR, Sarkis CM, DeMartino MG et al: Oral administration of cefixime to low risk febrile neutropenic children with cancer, Cancer 2000;88:2848-52.
• 35. Rackoff WR, Ge J, Sather HN, Cooper HA, Hutchinson RJ, Lange BJ: Central venous catheter use and risk of infection in children with acute lymphoblastic leukemia. A report from the children’s cancer group, J Pediatr Hematol Oncol 1999;21:260-7.
• 36. RackoffWR,Gonin R,Robinson C,Kreissman SG, Breitfeld PP: Predicting the risk of bacteremia in children with fever and neutropenia, J Clin Oncol 1996;14:919-24.
• 37. Saarinen-PihkalaUM, LanningM,Perkkiö M et al:Granulocytemacrophage colony-stimulating factor support in therapy of high risk acute lymphoblastic leukemia in children, Med Ped Oncol 2000;34:319-27.
• 38. Santolaya ME, Alvarez AM, Becker A et al: Prospective multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, fever, J Clin Oncol 2001;19:3415- 21.
• 39. Shenep JL, Flynn PM, BakerDK et al:Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer, Clin Infect Dis 2001;32:36-43.
• 40. Spanik S, Trupl J, Kunova A et al: Risk factors, etiology, therapy and outcome in 123 episodes in breakthrough bacteremia and fungemia during antimicrobial prohylaxis and therapy in cancer patients, J Med Microbiol 1997;46:517-23.
• 41. TaçyıldızN,AysevD,GençgönülHet al: Six years experience of fungemia in a pediatric oncology center in Turkey, Hematol J 2002;1:423.
• 42. Taçyıldız N, Kutluk T: Pediatrik febril nötropeni kılavuzu: Risk grupları ve ampirik tedavi seçenekleri , Flora 2004;9:73-105.
• 43. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia: A prospective, two cancer validation of a prediction rule, J Clin Oncol 1992;10:316-22.
• 44. Viscoli C: The evolution of the empirical management of fever and neutropenia in cancer patients, JAntimicrob Chemother 1998;41(Suppl D):65-80.
• 45. Weinstein MP: Current blood culture methods and systems: Clinical concepts, technology, and interpretation of results, Clin Infect Dis 1996; 23:40-60.